Work

Authors’ Reply

Year: 2019
Type: letter
Abstract: We read with interest the study by Hong et al 1 on stage migration in small cell lung cancer (SCLC) after increased FDG-PET use.The authors postulate that this led to improved survival because appropriate treatment was delivered due to accurate staging provided by FDG-PET.The authors should be commended for reporting data from a large retrospective cohort.However, as they acknowledged, there are many confounders and selection biases in this study that limit the ability to draw firm conclusions.For this reason, their findings do not provide sufficient evidence to support the routine clinical use of FDG-PET/CT in SCLC.The survival improvement reported over the course of the study could be due to improvements in supportive care or chemoradiotherapy delivery techniques, both unaccounted for in their analysis.Hong et al compare their outcomes to those of the CONVERT trial, 2 in which 57% of patients were staged with FDG-PET/CT in addition to conventional imaging (thorax/ abdomen CT, brain imaging 6 bone scintigraphy).We would like to note our re-
Institution: Duke University
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4245163428
Cites: 4
Cited by:
Related to: 10